Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1961 1
1962 1
1963 1
1965 1
1967 1
1987 1
1988 4
1989 2
1990 3
1991 1
1993 1
1995 1
1996 2
1999 2
2000 4
2001 2
2002 3
2003 2
2006 1
2007 2
2008 4
2009 6
2010 8
2011 13
2012 9
2013 10
2014 5
2015 3
2016 12
2017 5
2018 16
2019 17
2020 14
2021 20
2022 12
2023 21
2024 18
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Results by year

Filters applied: . Clear all
Page 1
Engineering altered protein-DNA recognition specificity.
Bogdanove AJ, Bohm A, Miller JC, Morgan RD, Stoddard BL. Bogdanove AJ, et al. Among authors: morgan rd. Nucleic Acids Res. 2018 Jun 1;46(10):4845-4871. doi: 10.1093/nar/gky289. Nucleic Acids Res. 2018. PMID: 29718463 Free PMC article. Review.
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
Morgan RD, Wang X, Barnes BM, Spurgeon L, Carrot A, Netto D, Hasan J, Mitchell C, Salih Z, Desai S, Shaw J, Winter-Roach B, Schlecht H, Burghel GJ, Clamp AR, Edmondson RJ, You B, Evans DGR, Jayson GC, Taylor SS. Morgan RD, et al. Br J Cancer. 2024 Dec;131(12):1919-1927. doi: 10.1038/s41416-024-02874-6. Epub 2024 Nov 16. Br J Cancer. 2024. PMID: 39550490 Free PMC article.
Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
Manchanda R, Sun L, Sobocan M, Rodriguez IV, Wei X, Kalra A, Oxley S, Sideris M, Fierheller CT, Morgan RD, Chandrasekaran D, Rust K, Spiliopoulou P, Miller RE, Crusz SM, Lockley M, Singh N, Faruqi A, Casey L, Brockbank E, Phadnis S, Mills-Baldock T, El-Khouly F, Jenkins LA, Wallace A, Ahmed M, Kumar A, Swisher EM, Gourley C, Norquist BM, Evans DG, Legood R. Manchanda R, et al. Among authors: morgan rd. J Natl Compr Canc Netw. 2024 Apr 18;22(2 D):e237331. doi: 10.6004/jnccn.2023.7331. J Natl Compr Canc Netw. 2024. PMID: 38866043
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC. Morgan RD, et al. Clin Cancer Res. 2023 Jul 14;29(14):2602-2611. doi: 10.1158/1078-0432.CCR-22-3282. Clin Cancer Res. 2023. PMID: 36799931
202 results